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The nasal microbiome in
granulomatosis with polyangiitis
Granulomatosis with polyangiitis (GPA,
formerly Wegener’s granulomatosis) is
a chronic relapsing autoimmune disease.
Mostpatients are aﬀectedbyear, nose and
throat (ENT) manifestations [1], which
may lead to chronic epistaxis, crusting,
impairedolfactionandpossiblydeforma-
tional changes (e.g. saddle nose defor-
mity). Nasal colonization with Staphy-
lococcus aureus may be a substantial en-
vironmental inﬂuence implicated in the
etiopathogenesis of GPA [2]. Of impor-
tance, Staphylococcus aureus represents
animportantopportunisticpathogenand
permanently lives as a commensal in
20–30%ofthegeneralpopulationandin-
termittently in approximately 60%. Col-
onization with Staphylococcus aureus is
an accepted risk factor for infections,
which is independent of the particular
strain [3]. In patients with GPA, the
presence of chronic Staphylococcus au-
reus colonizationexaminedbynasal swab
cultures indicates an independent risk
factor for relapse ofGPAwhen compared
to non-carriers. In this large single cen-
tre (AE) investigation the percentage of
chronic carriers was 63%. Chronic car-
rierswere deﬁned as the presence of posi-
tive cultures in ≥75% [4]. A prospective,
randomized, placebo-controlled study to
evaluatetheeﬃcacyoftrimethoprim-sul-
famethoxazole twice daily for 24 months
revealed a signiﬁcant reductionofdisease
relapses in patients with GPA. In addi-
tion, a signiﬁcantreductionof respiratory
and non-respiratory tract infections was
reported in patients with trimethoprim-
sulfamethoxazole treatment [5]. A recent
study showed signiﬁcantly higher nasal
Staphylococcus aureuscarriage inpatients
with GPA (72 %) compared to chronic
rhinosinusitispatients (28 %)andhealthy
controls. Patients with chronic nasal
Staphylococcus aureus carriage had sig-
niﬁcantly higher endoscopically proven
endonasal activity, signiﬁcantly more of-
ten initial manifestation in the ENT tract
and a non-signiﬁcantly higher relapse
rate (p = 0.052) than patients without
carriage [6]. Notably, the pathogenic-
ity of Staphylococcus aureus in GPA pa-
tients may be at least in part attributed
to the production of pyrogenic toxins.
Diverse antigens of Staphylococcus au-
reus have been identiﬁed in patients with
GPA. Among these superantigens (SAg),
the toxic shock syndrome toxin-1 (tsst-1)
is one of the most virulent. A retrospec-
tive longitudinal cohort study revealed
that a high proportion of GPA patients
(>70%) carried at least one Staphylococ-
cus aureus SAg. In general, the presence
of Staphylococcus aureus was accompa-
nied by a higher risk for relapse, while
theriskwasmodulatedbythe typeofSAg,
with tsst-1 being most strongly associ-
ated with disease relapse. The number of
patients positive for Staphylococcus au-
reus tsst-1 was signiﬁcantly higher with
36% compared to the general population
[7].
Rituximab, a monoclonal antibody
targeting CD20 bearing cells, has been li-
censed in the treatment of antineutrophil
cytoplasmic antibody (ANCA)-associ-
ated vasculitis. Although non-inferior
in both randomized, controlled trials,
adverse events (e.g. serious infections)
were comparable [8, 9]. In an elegant
retrospective study, Besada et al. investi-
gated the role of maintenance rituximab
treatment. Chronic carriage rates were
not inﬂuencedbythe treatment; however,
an increase in transient Staphylococcus
aureus carriage could be observed with
virtually no eﬀect on infections, relapse
or hypogammaglobulinemia [10].
Examination of nasal epithelial cells
obtained from patients with GPA and
normal controls indicated a signiﬁcant
up-regulation of granulocyte-colony
stimulating factor, whereas interleukin-
8 concentrations were reduced. After
stimulation with supernatants of Staphy-
lococcus aureus, GPA patients displayed
a signiﬁcantly lower interleukin-8 secre-
tion and a diminished dynamic range
of response towards the stimuli. These
ﬁndings indicate an impaired inﬂamma-
tory response and a reduced response to
a microbial stimulation leading to alter-
ations of the microbial composition of
the nostrils [11]. Antimicrobial peptides
from patients with either Staphylococcus
aureus colonization or negatives were
assessed by ELISA. In patients with
colonization signiﬁcantly higher levels
of LL-37 could be detected and after
stimulation with Staphylococcus aureus
signiﬁcantly higher levels of LL-37 and
human ß-defensin 3 could be detected in
the supernatant of nasal epithelial cells
of GPA patients [12]. A transcriptomic
approach revealed diﬀerential expression
of 10 transcripts including antimicrobial
transcripts, such as human beta-defensin
1, lysozyme and human beta-defensin 4;
however, the expression of these tran-
scripts did not correlate with Staphylo-
coccus aureus colonization [13]. Further
investigations of nasal epithelia revealed
an impaired ciliary beat frequency which
almost stagnated after 24 h. A signiﬁ-
cant correlation of impaired ciliary beat
frequency with the cumulative number
of immunosuppressive agents could be
found [14]. More recently, a study in-
dicated lower anti staphylococcal IgG
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levels against 59 Staphylococcus aureus
antigens in GPA patients compared to
healthy controls despite similar over-
all IgG levels. Moreover, an increased
frequency of resistant Staphylococcus
aureus strains towards trimethoprim-
sulfamethoxazole or ciproﬂoxacin was
observed over time [15]. The former
ﬁnding was not correlated with ritux-
imab treatment, which is known to
impair antibody response as shown in
vaccination studies.
Taken together, a pivotal role of
Staphylococcus aureus carriage in GPA
has been proposed by several authors.
The high number of chronic colonization
exceeds the number observed in the gen-
eral population. Several pathophysiolog-
ical considerations have been published
which may explain the pathogenicity of
Staphylococcus aureus in GPA, mainly
a reduced IgG response towards Staphy-
lococcus aureus and several molecular
alterations along with an abundance
of antimicrobial peptides. Novel tech-
niques, especially microbiome analysis
using either 16 S PCR or whole shotgun
sequencing will allow us to decipher the
causality whether Staphylococcus aureus
is implicated in the etiopathogenesis or
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